Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis
Arthritis Care & Research · 2026-10 · 78 (10) · 1532-1543
DOI: 10.1002/acr.80033 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Arthritis Care & Research, online erschienen am 02.04.2026. Verfasst von Narsis Daftarian und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Rheumatic Diseases, Hydroxychloroquine, Antirheumatic Agents, Retinal Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Objective
We aimed to estimate the prevalence and cumulative incidence of hydroxychloroquine retinopathy (HCQ‐R) and its risk factors among patients receiving long‐term HCQ with rheumatic diseases through a systematic review and meta‐analysis of observational studies that used spectral‐domain optical coherence tomography (SD‐OCT) for screening.
Methods
A systematic search of PubMed, Scopus, Ovid EMBASE, and World Health Organization databases (inception–December 31, 2025) identified observational studies meeting the following criteria: 1) adults with rheumatic diseases on HCQ for at least one year, 2) SD‐OCT used for HCQ‐R screening, 3) reported HCQ‐R prevalence or cumulative incidence or calculable data, 4) reported HCQ‐R risk factors as hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs), and 5) English full text. Study quality was assessed using the Newcastle–Ottawa Scale. Random‐effects meta‐analysis estimated pooled prevalence, cumulative incidence, and risk‐factor associations.
Results
We screened 827 studies from which an overall 19 met inclusion criteria (18 cohort and 1 case‐control). Pooled HCQ‐R prevalence from 2008 to 2023 was 5.1% (95% CI 3.9–6.5). Pooled cumulative incidence was 0.1% (95% CI 0.0–0.5) at 5 years, 2.6% (95% CI 1.6–4.1) at 10 years, and 5.6% (95% CI 3.2–9.6) at 15 years. Risk factors measured as HR (95% CI) included daily dose >5 mg/kg actual body weight (4.32 [2.80–6.65]), chronic kidney disease (CKD) (1.94 [1.27–2.96]), female sex (3.78 [1.90–7.48]), and Asian vs White ethnicity (1.67 [1.07–2.62]).
Conclusion
HCQ‐R risk increases with duration and is dose‐dependent, reaching 5.6% by 15 years. Findings support dose optimization with intensified screening for higher‐risk patients, including those with CKD or those who are female and/or Asian.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of British Columbia, Vancouver, British Columbia, Canada.
- Arthritis Research Canada, Vancouver, British Columbia, Canada.
- Simon Fraser University, Burnaby, British Columbia, Canada.
ORCID-Profile: Narsis Daftarian, Chloe Yue, Hui Xie, J Antonio Avina-Zubieta
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Daftarian, N., Yue, C., Levasseur, S. D., Xie, H., & Avina-Zubieta, J. A. (2026). Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis. Arthritis Care & Research, 78(10), 1532-1543. https://doi.org/10.1002/acr.80033
Vancouver
Daftarian N, Yue C, Levasseur SD, Xie H, Avina-Zubieta JA. Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis. Arthritis Care & Research. 2026;78(10):1532-1543. doi:10.1002/acr.80033
BibTeX
@article{Daftarian2026,
author = {Daftarian, Narsis and Yue, Chloe and Levasseur, Steve D and Xie, Hui and Avina-Zubieta, J Antonio},
title = {Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis},
journal = {Arthritis Care & Research},
year = {2026},
volume = {78},
number = {10},
pages = {1532--1543},
doi = {10.1002/acr.80033}
}
EUVIMED